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ABSTRACT 
 
DNA methylation has fundamental roles in gene programming and aging that may help predict mortality. 
However, no large-scale study has investigated whether site-specific DNA methylation predicts all-cause 
mortality. We used the Illumina-HumanMethylation450-BeadChip to identify blood DNA methylation sites 
associated with all-cause mortality for 12, 300 participants in 12 Cohorts of the Heart and Aging Research in 
Genetic Epidemiology (CHARGE) Consortium. Over an average 10-year follow-up, there were 2,561 deaths 
across the cohorts. Nine sites mapping to three intergenic and six gene-specific regions were associated with 
mortality (P < 9.3x10-7) independently of age and other mortality predictors. Six sites (cg14866069, 
cg23666362, cg20045320, cg07839457, cg07677157, cg09615688)—mapping respectively to BMPR1B, 
MIR1973, IFITM3, NLRC5, and two intergenic regions—were associated with reduced mortality risk. The 
remaining three sites (cg17086398, cg12619262, cg18424841)—mapping respectively to SERINC2, CHST12, 
and an intergenic region—were associated with increased mortality risk. DNA methylation at each site 
predicted 5%–15% of all deaths. We also assessed the causal association of those sites to age-related chronic 
diseases by using Mendelian randomization, identifying weak causal relationship between cg18424841 and 
cg09615688 with coronary heart disease. Of the nine sites, three (cg20045320, cg07839457, cg07677157) 
were associated with lower incidence of heart disease risk and two (cg20045320, cg07839457) with smoking 
and inflammation in prior CHARGE analyses. Methylation of cg20045320, cg07839457, and cg17086398 was 
associated with decreased expression of nearby genes (IFITM3, IRF, NLRC5, MT1, MT2, MARCKSL1) linked to 
immune responses and cardiometabolic diseases. These sites may serve as useful clinical tools for mortality 
risk assessment and preventative care. 
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INTRODUCTION 
 
The human epigenome contains DNA methylation marks 
that progressively change as we age. DNA methylation 
can influence gene expression and manifests in response 
to both environmental and hereditary factors [1, 2]. 
Biological age estimations, constructed from DNA 
methylation marks and referred to as “epigenetic aging 
clocks”, have been associated with environmental 
exposures, morbidities, and mortality [9–13]. As these 
clocks were designed to track chronological age, not to 
predict mortality, further study is necessary to fully 
elucidate indicators of all-cause mortality. To date, no 
large-scale analysis has been conducted to identify 
variations in DNA methylation at individual 5’-cytosine-
phosphate-guanosine-3’ (CpG) sites associated with 
future mortality risk. Here, we present an epigenome-
wide methylation analysis of 12,300 participants and 2, 
561 (21%) deaths from 12 American and European 
cohorts to determine whether site-specific DNA 
methylation predicts all-cause mortality, independent of 
age, lifestyle factors, and clinical predictors of mortality 
including comorbidities. We also assessed the causal 
relationship of identified sites with age-related chronic 
diseases using Mendelian randomization approaches, and 
we related the sites to epigenetic aging clocks and a 
mortality risk score, an epigenetic indicator of mortality 
previously created and validated with DNA methylation 
arrays in two European cohorts. 
 
RESULTS 
 
Cohorts 
 
Across studies in the Cohorts of the Heart and Aging 
Research in Genetic Epidemiology (CHARGE) 
Consortium, mortality rates ranged from 3%–70% of all 
participants, and the average time to death or censoring 
ranged from 4.4–16.6 years (Supplementary Table 1). 
Each study conducted epigenome-wide mortality 
analyses, adjusting for two sets of harmonized risk 
factors and confounders, and shared results for meta-
analysis (Figure 1). 
 
Meta-analysis 
 
Inverse variance-weighted fixed-effects meta-analysis of 
426, 724 CpGs identified 51 Bonferroni-significant and 
 
 
 
Figure 1. Workflow of the study. 
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257 FDR-significant (P < 3.03x10-5) CpGs in a basic 
model adjusting for age, sex, technical covariates, and 
white blood cell proportions (Figure 2A and 
Supplementary Table 2). We also identified three 
Bonferroni-significant and nine FDR-significant (P < 
9.3x10-7) CpGs in a fully-adjusted model also adjusting 
for education, smoking status, pack-years smoked, body 
mass index, recreational physical activity, alcohol 
consumption, hypertension, diabetes, and history of 
cancer and coronary heart disease (Figures 2B, 3A  
and Supplementary Table 3). For 188 (73%) basic-
adjusted FDR-significant CpGs and six (67%) fully-
adjusted CpGs, higher blood DNA methylation was 
associated with lower all-cause mortality (Figure 2 and 
Supplementary Tables 2, 3). 
 
All nine fully-adjusted FDR-significant CpGs had 
similar magnitude of associations with mortality in the 
basic model, although only five were also FDR-
significant in the basic model (Figure 3B). Hazard ratios 
(HRs) of the nine fully-adjusted FDR-significant CpGs 
ranged 0.53–1.26 per 10% increase in DNA methylation 
levels, where 1 represents 100% methylation 
(Supplementary Table 4). Six sites (cg14866069, 
cg23666362, cg20045320, cg07839457, cg07677157, 
cg09615688) were associated with reduced mortality 
risk, while the remaining three sites (cg17086398, 
cg12619262, cg18424841) were associated with 
increased mortality risk (Figure 3A and Supplementary 
Tables 3, 4). Three fully-adjusted CpGs (cg07677157, 
cg09615688, cg18424841) were in intergenic regions; the 
remaining six (cg17086398, cg14866069, cg23666362, 
cg12619262, cg20045320, cg07839457) were within 
10,000 bp of a gene, with two CpGs (cg07839457, 
cg23666362) mapped respectively to nucleotide-binding 
oligomerization domain-like receptor caspase recruitment 
domain containing 5 (NLRC5) and microRNA 1973 
(MIR1973) within 1,500 bp of transcription start sites, 
and one (cg17086398) in the serine incorporator 2 
(SERINC2) gene body (Supplementary Table 3). 
 
Meta-analysis results did not appear to suffer from 
systematic bias due to unmeasured confounding, as 
assessed by genomic inflation (basic model: λ = 1.12, 
 
 
 
Figure 2. Quantile-Quantile plots, Manhattan and Volcano for the basic model (Panel A) and for the fully adjusted model (Panel B). 
 www.aging-us.com 14096 AGING 
fully adjusted model λ = 0.94, Figure 2 and 
Supplementary Table 5). Cohort-specific inflation was 
also minimal, with lambdas close to one for most cohorts. 
Volcano plots showed symmetry in the direction of the 
associations with all-cause mortality (Figure 2). All  
nine fully-adjusted FDR-significant CpGs showed 
low/medium heterogeneity (Supplementary Tables 7) and 
consistent magnitude of the estimated HRs across studies 
(Figure 3A). We further validated our results by 
excluding cohorts with high proportion of deaths (30%) 
and inflation (λ > 1.5). In these sensitivity analyses, HRs 
for the nine FDR-significant CpGs were consistent with 
main results in terms of direction, magnitude, and 
statistical significance (Supplementary Figure 1 and 
Supplementary Tables 8, 9). 
 
Three of the nine fully-adjusted FDR-significant  
CpGs (cg20045320, cg07677157, cg07839457) were 
associated with lower incidence of coronary heart 
disease rates (P < Bonferroni threshold of 0.005) 
(Figure 4 and Supplementary Table 10). 
 
Miettinen’s population attributable factor, epigenetic 
aging clocks, and mortality risk score 
 
To assess the extent that methylation levels of each CpG 
predict all-cause mortality, we calculated Miettinen’s 
population attributable fraction on data from the 
Normative Aging Study (NAS) and the Women Health 
Initiative-Epigenetic Mechanisms of Particulate Matter-
Mediated Cardiovascular Disease (WHI-EMPC) for 
European and African American ancestries. DNA 
methylation levels above the average at each CpG 
predicted, individually and independently of other 
factors, 5%–15% of all deaths (Figure 3C and 
Supplementary Table 11). In the same datasets, all nine 
CpGs were associated with age, cumulative smoking, 
body mass index, and physical activity (P < 0.05). Seven 
out of nine CpGs (cg17086398, cg14866069, 
cg23666362, cg20045320, cg7677157, cg07839457, 
cg09615688) had negative relationships with age 
(Supplementary Table 12). Seven CpGs were strongly 
associated with epigenetic aging clocks and mortality 
risk scores; all significant associations had the same 
direction and similar magnitude across the four 
epigenetic aging clocks (Supplementary Table 13), even 
if none of those sites was included in any of the clocks. 
Those CpGs had consistent and independent association 
with all-cause mortality when adjusted for epigenetic 
aging clocks and mortality risk scores (Supplementary 
Tables 14, 15). In overall meta-analysis, we identified 57 
out of 58 CpGs of the risk score, and those sites had low 
to moderate association with DNA methylation levels at 
our FDR-significant CpGs with a balance between 
 
 
 
Figure 3. (A) Forest Plots for the association of methylation levels of the FDR-significant fully-adjusted CpGs with risk of all-cause mortality in 
the CHARGE consortium. (B) Sensitivity analysis. Comparison of the hazard ratio of the basic-adjusted and the fully-adjusted fixed effect 
meta-analysis. (C) Attributable factor. Predicted Contribution (%) of increased methylation levels (above the mean) of each CpG to the all-
cause mortality associations in NAS, WHI-EMPC (EA) and WHI-EMPC (AA). (D) Functional Mapping and Annotation results in order to examine 
tissue specificity of the genes mapped to the FDR-significant fully-adjusted CpGs. 
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positive and negative correlations (Supplementary 
Figure 2A, 2B). In overall meta-analysis, the association 
between all-cause mortality and DNA methylation levels 
at the majority (34 out of 58) of mortality risk score 
CpGs had consistent direction with previous results. 
Among those CpGs, only two (cg25193885 and 
cg19859270) showed nominally significant association 
with mortality (Supplementary Figure 2A, 2B). 
 
Pathways analyses and DNA methylation integration 
with quantitative trait loci analysis (meQTL) and 
with gene expression (eQTM) 
 
Extended genome-wide enrichment analysis showed that 
two of the CpGs (cg07839457 and cg17086398) mapped 
to genes (NLRC5 and SERINC2, respectively) previously 
associated with high-density lipoprotein cholesterol 
levels (FDR P = 0.02) and alcohol dependence (FDR 
P = 0.004) in genome-wide association studies (GWAS) 
analyses (Supplementary Table 16) [14]. We confirmed 
these results using Database for Annotation, 
Visualization and Integrated Discovery (DAVID) and 
KEGG, identifying and testing for enriched underlying 
biological processes in publicly available gene ontology 
databases (Supplementary Tables 17, 18). 
 
To characterize the functional relevance of FDR-
significant CpGs, we performed covariate-adjusted 
methylation quantitative trait locus (meQTL) analyses 
using available unique single-nucleotide-polymorphism 
(SNP)–CpG combinations from 713 participants  
in the Cooperative Health Research in the Region 
Augsburg (KORA) study [15]. We identified  
nine Bonferroni-significant unique cis-regulatory 
polymorphisms associated with two 1000 bp-distant 
CpGs (cg09615688, cg18424841) (Supplementary 
Figure 3A and Supplementary Table 19). None of the 
nine identified polymorphisms overlapped with 
previous genetic results from the National Human 
Genome Research Institute-EBI GWAS Catalog 
(Supplementary Table 16). 
We also evaluated expression quantitative trait 
methylation (eQTM) associations using 998 KORA 
participants. We identified three CpGs with FDR-
significant associations with decreased leukocyte 
expression levels of nearby genes, among the 13, 351 
unique associations between gene-expression and DNA 
methylation levels at FDR-significant fully-adjusted 
CpGs. Namely, DNA methylation levels of cg07839457 
(in NLRC5) were associated with NLRC5 expression as 
well as with that of a ~300 Mb-distant set of 
metallothionein (MT) 1 and 2 genes, which are linked to 
oxidative stress and immune responses [16, 17]. DNA 
methylation of cg17086398 in SERINC2 was inversely 
associated with myristoylated alanine-rich C-kinase 
substrate like 1 (MARCKSL1) expression, which is 
involved in migration of cancer cells [18]. DNA 
methylation at cg20045320 in IFITM3 was associated 
with lower expression of IFITM3 and IRF, which have a 
critical role in immune responses (Supplementary 
Figure 3B and Supplementary Table 20) [6, 19]. 
 
We finally used functional mapping and annotation to 
examine tissue-specific expression. Genes identified in 
the fully-adjusted model showed universal expression at 
varying levels across tissues. IFITM3 was highly 
expressed in all tissues; BMPR1B showed low 
expression across all tissues, except for moderate 
expression in the prostate and tibial nerve. Remaining 
genes had moderate or low expression in a wide range 
of tissues, except for SERINC2, which showed high 
expression in the liver, kidney, salivary gland, and 
esophagus. MIR1973 was not represented in the dataset 
(Figure 3D). 
 
Mendelian randomization 
 
To evaluate the causal relationship of FDR-significant 
CpGs to mortality-related risk factors and diseases, we 
included two sets of Mendelian randomization analysis 
using methQTL data from KORA and publicly available 
ARIES data. Only two FDR-significant CpGs 
 
 
 
Figure 4. Forest Plots for the association of methylation levels of the FDR-significant fully-adjusted CpGs with risk of future 
incident coronary heart disease in the CHARGE consortium. 
 www.aging-us.com 14098 AGING 
(cg18424841 and cg09615688) overlapped with 
methQTLs in either KORA or ARIES and with SNPs 
associated with coronary heart disease (CHD) or kidney 
function. A GWAS assessing longevity and age-related 
chronic diseases (CHD and kidney function) [34–38] 
showed no overlap with KORA and ARIES methQTLs 
even when using a moderate threshold for proxy variants 
(proxy r2 > 0.75). In KORA, cg09615688 showed 
evidence of a positive causal effect on CHD (OR = 1.51; 
95% CI = 1.02, 2.23; Wald ratio method), directionally 
consistent with the association of overall meta-analysis 
on mortality. However, this causal estimate at this site 
was not represented in ARIES methQTL data. 
Cg18424841 had multiple variants in KORA methQTL 
data and a single variant in ARIES methQTL data. We 
did not observe consistent evidence of a causal effect of 
cg18424841 on CHD. Indeed, weak evidence for a 
causal effect of cg18424841 on CHD was observed in 
ARIES using the Wald ratio method but not in KORA 
using pleiotropy-robust, multi-variant, or Wald ratio 
methods. We did not find evidence for a causal effect of 
cg18424841 on kidney function in either KORA or 
ARIES (Supplementary Table 21). 
 
Cell-type fractions and all-cause mortality 
 
Cell-type fractions, mostly neutrophil–lymphocyte ratio 
(NLR), have been often associated with comorbidities 
and mortality and have been recognized to influence 
DNA methylation levels [20–22]. We identified that 
NLR was significantly associated with all-cause 
mortality only when data were not adjusted for 
Houseman cell proportions using NAS data 
(Supplementary Table 22). Interestingly, NLR had no 
significant association with all-cause mortality when we 
adjusted for DNA methylation levels at cg07839457, 
mapped to immune-related gene NLRC5. However, the 
contribution of NLR on mortality at that specific site 
may be minimized due to adjustment of prior history of 
cancer and comorbidities in all models. 
 
DISCUSSION 
 
This study is the largest to date investigating site-
specific DNA methylation and all-cause mortality. We 
identified new whole blood DNA methylation marks 
that predict all-cause mortality risk, independent from 
chronological age, lifestyle habits, and morbidity. These 
newly identified sites may be useful in developing 
clinical tools for risk assessment and mortality 
preventive intervention strategies. 
 
All nine FDR-significant CpGs demonstrated novel 
association with all-cause mortality and were not part of 
epigenetic aging clocks or mortality risk scores [9, 11–
13]. Further, the CpGs were associated with mortality 
independent from epigenetic aging and mortality 
signatures. All-cause mortality was associated with a 
mortality risk score in a model including seven FDR-
significant CpGs, although those associations may be 
driven by the inclusion of CpGs related to our FDR-
significant sites. This suggests that whole blood DNA 
methylation levels at FDR-significant CpGs may be 
sentinels for epigenetic disruptions leading to aging 
acceleration and contributing to mortality. In addition, 
the association between DNA methylation levels at 
FDR-significant CpGs with chronological aging may 
suggest that those CpGs are stronger independent 
biomarkers of aging than other epigenetic aging 
signatures. 
 
In previous CHARGE meta-analyses [3, 4], DNA 
methylation of two of the newly-identified CpGs, 
cg20045320 and cg07839457 (mapping to interferon 
induced transmembrane protein 3 [IFITM3] and NLRC5) 
were respectively associated with smoking and 
cardiovascular-related chronic inflammation, both 
factors of mortality. Cardiovascular disease, especially 
CHD, is a major contributor to mortality [23]. The 
direction of association with incident heart disease was 
consistent with that of all-cause mortality. Thus, DNA 
methylation at these CpGs may contribute to 
development and progression of CHD and, 
consequently, to risk of death. To validate this idea, we 
used a Mendelian randomization approach and identified 
one site, cg09615688, with a causal effect on CHD in 
KORA data and weak evidence for the causal effect of 
cg18424841 on CHD in ARIES data. 
 
Expression of several genes mapped to the fully-
adjusted FDR-significant CpGs has been associated 
with mortality predictors and mortality. Elevated and 
persistent gene expression levels of NLRC5, a master 
regulator of the immune response [16], has 
demonstrated an inverse correlation with familial 
longevity and mortality predictors, such as elevated 
blood pressure, arterial stiffness, chronic levels of 
inflammatory cytokines, metabolic dysfunction, and 
oxidative stress [5]. In addition, expression of IFITM3 
provides an essential barrier to influenza A virus 
infection in vivo and in vitro. Absence of IFITM3 leads 
to uncontrolled viral replication and a predisposition to 
morbidity and subsequent mortality [6]. Further, 
expression of BMPR1B enhances cancer cell migration, 
and approaches targeting BMPR1B inhibit metastatic 
activity in breast cancer [7]. Finally, expression of 
MIR1973, part of a family of microRNAs, increases 
resistant lung adenocarcinoma cells, with subsequent 
low apoptosis intensity [8]. This body of evidence may 
suggest an active role of DNA methylation levels in 
regulating relevant gene expression and reducing all-
cause mortality risk. 
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The overall meta-analyses included 12 cohorts with 
varying biological age and mortality. There was a 
balance between six studies with long (≥10 years) and 
six cohorts with short (<10 years) average time to 
follow-up or death. All cohorts showed consistency in 
magnitudes and directionality for the association with 
mortality of four CpGs (cg12619262, cg20045320, 
cg07839457, cg18424841). Two studies (FHS study 1 
and KORA) showed non-significant opposing 
directionality when compared with the rest of the 
cohorts for several CpGs (FHS-Study 1: cg14866069, 
cg23666362, cg09615688; KORA: cg17086398, 
cg14866069, cg23666362). However, both cohorts had 
among the shortest average time-to-death (FHS-Study 
1: 6.1 years; KORA: 4.4 years) and youngest average 
population age (FHS-Study 1: 65 years; KORA: 61 
years). Both cohorts also had limited contribution in our 
meta-analysis due to reduced number of deaths (FHS-
Study 1: 62; KORA: 42). Our results may indicate that 
DNA methylation levels at these select CpGs were 
relevant for mortality risk prediction of longer time-to-
death in both adults and older-age adults. 
 
Cell-type fractions, including NLR, as related to cancer 
and systemic inflammation have been related to 
mortality in different populations [20–22]. When we 
excluded Houseman cell proportions, NLR was strongly 
associated with mortality at all CpGs except 
cg07839457, which is mapped to the immune-related 
gene NLRC5. This may suggest that the contribution of 
NLR on mortality is minimized when controlled for 
prior history of cancer and related comorbidities. 
 
In summary, we identified nine CpGs with a novel 
association with all-cause mortality, responsive to 
several external stimuli including alcohol consumption 
and smoking, and more than 10 years before death. 
These sites thus may be considered sentinels for 
epigenetic disruptions leading to age-related disease, 
such as cardiovascular disease, and contributing to 
mortality. Further studies have to confirm these 
associations in other tissues and in different populations. 
 
MATERIALS AND METHODS 
 
Participating cohort studies 
 
Our meta-analysis included 12,300 participants from 12 
population-based cohorts of the Heart and Aging 
Research in Genetic Epidemiology Consortium 
(CHARGE; Supplementary material): Atherosclerosis 
Risk In Communities (ARIC), two studies from the 
Framingham Heart Study (FHS), Invecchiare in Chianti 
(InChianti), Kooperative Gesundheitsforschung in der 
Region Augsburg (KORA), Lothian Birth Cohort 1921 
(LBC1921) and 1936 (LBC1936), Normative Aging 
Study (NAS), UK Adult Twin Registry (TwinsUK), and 
three studies from the Women’s Health Initiative 
(WHI), including Broad Agency Announcement 23 
(WHI-BAA23) and Epigenetic Mechanisms of PM-
Mediated CVD Risk (WHI-EMPC), both European 
(WHI-EMPC-EA) and African American ancestries 
(WHI-EMPC-AA). For each participant, we derived 
years of follow-up using time between the blood draw 
used for DNA methylation analysis and death or last 
follow-up. Each cohort excluded participants with 
diagnosed leukemia (ICD-9: 203–208) or undergoing 
chemotherapy treatment, which both modify blood-
derived data [24, 25]. All participating cohorts shared 
cohort descriptive statistics and results files from pre-
specified in-house mortality analyses (Figure 1). Further 
information about death ascertainment, covariates 
measurement and harmonization, protocols, and 
methods of each cohort are included in the 
Supplemental Materials. The institutional review 
committees of each cohort approved this study, and all 
participants provided written informed consent. Data 
and analytical codes that support our findings are 
available from the corresponding author upon request. 
 
Blood DNA methylation measurements and quality 
control 
 
Each cohort independently conducted laboratory DNA 
methylation measurements and internal quality control. 
All samples underwent bisulfite conversion via the  
EZ-96 DNA Methylation kit (Zymo Research) and  
were processed with the Illumina Infinium 
HumanMethylation450 (450K) BeadChip (Illumina) at 
Illumina or in cohort-specific laboratories. Quality 
control of samples included exclusion on the basis of 
Illumina’s detection P-value, low sample DNA 
concentration, sample call rate, CpG specific percentage 
of missing values, bisulfite conversion efficiency, gender 
verification with multidimensional scaling plots, and 
other quality control metrics specific to cohorts. Each 
cohort used validated statistical methods for normalizing 
methylation data on untransformed methylation beta 
values (ranging 0–1). Some cohorts also made 
independent probe exclusions. Further details are 
provided in the Supplemental Material. For meta-
analysis, additional probe exclusions were made across 
all cohorts. In detail, we also excluded control probes, 
non-CpG sites, probes that mapped to allosomal 
chromosomes, cross-reactive CpGs, probes with 
underlying SNPs within 10 bp of the CpG sequence, 
non-varying CpGs defined by interquartile range of 
<0.1%, CpGs with ≥10% of missing information, and 
CpGs with non-converging results [26–28]. We included 
only CpGs that were available in more than three 
cohorts. A total of 426, 724 CpGs were included in the 
meta-analysis (Supplementary Table 5). 
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The official gene name of each CpG site was noted via 
Illumina’s genome coordinate. We used the name 
provided by Illumina with the UCSC Genome Browser 
and annotation data in Bioconductor. All annotations use 
the human February 2009 (GRCh37/hg19) assembly. 
 
Cohort-specific statistical analyses 
 
Each cohort independently ran a common pre-specified 
statistical analysis in R.version 3.5.1. We estimated the 
association between locus-by-locus blood DNA 
methylation levels and all-cause mortality in each cohort 
using a Cox-regression model. Proportional hazard 
assumptions were confirmed for each model in all 
cohorts. Familial relationship was also accounted for, 
when appropriate, in the model; FHS analyses included 
cluster for family structure, and TwinsUK analyses used 
random intercepts for zygosity and family structure. To 
avoid non-convergent results, cohorts with low deaths 
(KORA and TwinsUK) used a two-step analysis, in 
which covariates were first linearly regressed on each 
probe, and then residuals were used to perform a Cox 
mortality analysis. 
 
Each cohort adjusted for harmonized covariates in the 
basic model: age (categories for decades), sex, and 
technical covariates (plate, chip, row, and column). A 
second set of fully-adjusted analyses adjusted for this 
initial list of covariates in addition to education level, 
self-reported recreational physical activity, smoking 
status, cumulative smoking (pack-years), body mass 
index, alcohol intake, hypertension, diabetes, and any 
personal history of cancer. Cohorts independently 
estimated cell type proportions using the reference-based 
Houseman method, which was subsequently extended by 
Horvath. Cell type correction was applied by including 
estimated cell type proportions (CD4T, NK cells, 
monocytes, granulocytes, plasma B cells, CD8T naïve, 
and memory and effector T cells) as covariates in cohort-
specific statistical models. Each cohort underwent 
statistical validation of Cox-proportional hazard 
assumptions before being included in the meta-analysis. 
 
Meta-analysis 
 
We performed inverse variance-weighted fixed-effects 
meta-analysis. Due to the variability of available CpG 
sites across cohorts after quality-control steps, we 
included only CpG sites that were available in three or 
more cohorts. We accounted for multiple testing by 
controlling at 5% both the Bonferroni correction and 
false discovery rate (FDR) using the Benjamini-
Hochberg procedure. 
 
For FDR-significant CpGs, we confirmed robustness of 
the models and results in additional analyses using the 
leave-one-out cohort validation method, by excluding 
one cohort at a time and then comparing model 
estimates for each CpG. We compared effect hazard 
ratio (HR) and 95% confidence interval (95% CI) for 
the model to estimates for our models to evaluate the 
consistency of our findings. For each CpG, we 
evaluated goodness of the meta-analysis model using 
the I² statistic measure of inter-study variability from 
random-effect meta-analyses. 
 
Enrichment analysis 
 
We enriched our results using a publicly available 
catalog of all published GWAS relating genetic variants 
with human diseases (National Human Genome 
Research Institute-EBI GWAS Catalog) to elucidate 
potential associations [14]. Enrichment analysis was 
performed in R using one-sided Fisher exact test. We 
controlled for false positives with the FDR procedure. 
 
We evaluated whether CpG sites associated with 
mortality were enriched with genomic features  
provided in the Illumina annotation file (version 1.2; 
http://support.illumina.com/array/array_kits/infinium_hu
manmethylation450_beadchip_kit/downloads.html) to 
identify CpG location relative to the gene (i.e., body, 
first exon, 3’-UTR, 5’-UTR, within 200 bp of 
transcriptional start site [TSS200]), and within 1500 bp 
of transcriptional start site [TSS1500]) and relation of 
the CpG site to a CpG island, northern shelf, northern 
shore, southern shelf, and southern shore. 
 
We also tested each gene mapped to the newly 
identified CpGs for tissue-specific expression using data 
from the Genotype Tissue Expression (GTEx) project as 
integrated by the Functional Mapping and Annotation 
(FUMA) tool [29], which allowed us to extract and 
interpret relevant biological information from publicly 
available repositories and provide interactive figures for 
prioritized genes. As a result, we obtained a heatmap of 
genes with normalized gene expression values (reads 
per kilo base per million). To obtain differentially 
expressed gene sets for each of 53 tissue types in the 
database, we used two-sided Student’s t-tests on 
normalized expression per gene per tissue against all 
other tissues. We controlled for multiple comparison 
with Bonferroni correction. Finally, we distinguished 
between genes upregulated and downregulated in a 
specific tissue compared to other tissues by accounting 
for sign of the t-score [29]. 
 
Pathway analyses 
 
To functionally interpret the genomic information 
identified from FDR-significant CpGs, we used the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) 
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pathway database, which links genomic information 
with higher-order functional information. Genomic 
information stored in the GENES database is a 
collection of gene catalogs for all completely sequenced 
genomes and some partial genomes with up-to-date 
annotation of gene functions. Higher-order functional 
information stored in the PATHWAY database contains 
graphical representations of cellular processes, such as 
metabolism, membrane transport, signal transduction, 
and cell cycle [30]. We controlled our results for 
multiple comparisons with the FDR approach. We 
finally confirmed our results with the Database for 
Annotation, Visualization and Integrated Discovery 
(DAVID). We tested for enrichment in gene ontology 
biological processes and applied the Benjamini-
Hochberg procedure to control for false positivity. We 
mapped each CpG significantly associated with mortality 
to genes on the basis of the 450K BeadChip annotation 
file. We excluded CpGs lacking annotated genes within 
10 Mb (n = 3). Using topGO in R, we tested for gene 
enrichment over the background array (16, 119 unique 
annotated Entrez Gene IDs) by using Fisher’s exact tests 
with a minimum of two genes per node. 
 
Integrating DNA methylation with quantitative trait 
loci analysis (meQTL) 
 
A subset of 713 KORA samples was genotyped on an 
Affymetrix Axiom array. We removed variants with a 
call rate of <0.98, Hardy-Weinberg equilibrium P < 
5x10-6, and minor allele frequency < 0.01. We 
considered only variants with an information score > 3. 
Imputation was performed using the 1000 Genomes 
Project phase I version 3 reference panel with IMPUTE 
2.3.0. Phasing of data was performed using SHAPEIT 
v2. We retained approximately 10,000,000 variants for 
analyses. In each model, we used DNA methylation 
beta values as independent variables and SNPs as 
dependent variables. We adjusted each model for age, 
sex, body mass index, and white blood cell proportions. 
We used OmicABEL [31] for the analyses and genotype 
probabilities for each variant. Due to large size  
of the output, we retained only variants with P < 1x10-4. 
We considered genome-wide significant results at  
P < 1x10-14. We reported only associations with CpGs 
significant in the epigenome-wide association study. 
 
Integrating DNA methylation with gene expression 
(eQTM) 
 
In KORA, 998 individuals had both valid methylation 
and blood gene expression data, which we used to 
assess whether DNA methylation was correlated with 
gene expression. Gene expression data (Illumina 
HumanHT-12 v3 Expression BeadChip) was quality 
controlled with GenomeStudio, and samples with 
<6,000 detected genes were excluded from analysis. All 
samples were log2-transformed and quantile-normalized 
using the Bioconductor package lumi [32]. A total of 
48,803 expression probes passed quality control. We 
used R (version 3.3.1) to run a linear mixed effects 
model adjusting for covariates (age, sex, blood cell 
proportions, and technical variables of RNA integrity 
number, sample storage time, and RNA amplification 
batch) and a random intercept for RNA amplification 
batch. Models were run for each of the nine newly-
identified CpGs associated with mortality. We filtered 
results to report only CpG-expression probe pairs 
located on the same chromosome. Start and end sites for 
each gene were determined according to the Illumina 
HT annotation file. A cutoff of 500,000 bp was used to 
differentiate cis- vs. trans-eQTMs. 
 
Miettinen’s population attributable factor and 
mendelian randomization analysis 
 
To assess the contribution of methylation levels of each 
CpG to all-cause mortality, we calculated Miettinen’s 
population attributable fraction on data from the in-
house Normative Aging Study (NAS) and Women 
Health Initiative-Epigenetic Mechanisms of Particulate 
Matter-Mediated Cardiovascular Disease (WHI-EMPC) 
for European and African American ancestries. 
Population attributable fraction takes into account 
strength of association between the risk factor (DNA 
methylation higher than the mean in specific CpG sites) 
and outcome (mortality) as well as prevalence of the 
risk factor in the population [33]. This metric provides 
estimates of the public health importance of risk factors, 
ascertaining what proportion of the outcome is due to 
exposure to the risk factor, and distinguishes between 
etiologic fraction attributable to or related to the given 
risk factor depending on whether all or just some 
confounding by extraneous factors was under control 
[33]. To support information about the population 
attributable factor, we also included two Mendelian 
randomization approaches. 
 
We identified the causal effect on all-cause mortality of 
FDR-significant CpGs by using two sample Mendelian 
randomization analyses and summary statistics from 
published GWAS for chronic diseases and longevity [34] 
and chronic diseases, including CHD [35], kidney 
function (serum creatinine), [36] blood pressure, [37] and 
type 2 diabetes [38]. We extracted GWAS information 
with MR-base [14]. We also extracted SNP-methylation 
association summary statistics from both KORA and 
publicly available ARIES [39] methQTL data; for 
ARIES, we used MR-base [40]. To account for multiple 
variants and pleiotropy, we used multiple Mendelian 
randomization methods—when only one variant was 
present, we used the Wald Ratio method [41]; when we 
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had multiple variants, we used MR Egger [42], 
weighted median [43], and weighted mode [44], as 
these three methods use different assumptions to 
provide consistent causal effect estimates even with 
invalid instruments arising from horizontal pleiotropy, a 
primary source of bias in multi-variant Mendelian 
randomization analyses. 
 
FDR-significant CpGs, DNA methylation-related 
aging measures, and mortality risk score 
 
PhenoAge, a composite measure of CpG sites 
representing phenotypic age, captures differences 
between lifespan and health span. The Horvath clock is 
a linear combination of sites identifying the cumulative 
effect of an epigenetic maintenance system [1, 45]. 
Among the 513 CpGs comprising PhenoAge, 41 are 
shared with the Horvath clock. While both aging 
measures correlate strongly with age in every tissue and 
cell type tested, and both captured risks for mortality 
across multiple tissues and cells, PhenoAge is highly 
predictive of nearly every morbidity [1, 10]. Blood 
PhenoAge outperformed the Horvath clock with regard 
to predictions for a variety of aging outcomes, including 
all-cause mortality. The mortality risk score instead was 
based on results using discovery cohort ESTHER (61 
years old on average) and both ESTHER and KORA for 
validation [11]. 
 
To investigate whether the association of FDR-
significant CpGs with mortality was independent of 
DNA methylation aging measures and risk score, we 
included acceleration of PhenoAge and Horvath clock, 
defined respectively as discrepancies between age with 
PhenoAge and Horvath clock age and the risk score. We 
also identified the correlation between each CpG 
included in the risk score and our FDR-significant 
CpGs, and we compared our pooled meta-analysis 
results with previous findings. 
 
Cell-type fractions and all-cause mortality 
 
Cell-type fractions, mostly NLR, influence DNA 
methylation levels and have been associated with 
comorbidities and mortality [20–22]. To elucidate which 
cell proportions were associated with mortality when 
adjusting for DNA methylation at FDR-significant CpGs, 
we included NLR, which has been associated with lung 
cancer risk and mortality [21] as well was cardiovascular 
disease and mortality in prospective studies [22]. NLR 
computation was performed using DNA methylation data 
via Koestler et al. [46] 
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SUPPLEMENTARY MATERIALS 
 
Supplementary material - cohort description 
 
The atherosclerosis risk in communities (ARIC) study 
 
ARIC cohort description 
The ARIC Study is a population-based prospective 
cohort study of cardiovascular disease risk in four US 
communities [1]. Between 1987 and 1989, 7,082 men 
and 8,710 women aged 45–64 years were enrolled in 
Forsyth County, North Carolina; Jackson, Mississippi 
(African Americans only); suburban Minneapolis, 
Minnesota; and Washington County, Maryland. The 
ARIC Study protocol was approved by the institutional 
review board of each participating university, and 
participants provided written informed consent. 
Participants underwent a baseline clinical examination 
(Visit 1) and four subsequent follow-up clinical exams 
(Visits 2–5). The present analysis is restricted to African 
Americans from Jackson and Forsyth County centers. 
Baseline for mortality follow-up is either Visit 2 (1990–
1992) or Visit 3 (1993–1995), when the DNA used for 
methylation quantification was collected. Covariates were 
measured at the time of blood draw, unless otherwise 
specified. Data on education, smoking status, smoking 
pack-years, alcohol intake, and physical activity were 
obtained by self-report at Visit 1. Trained technicians 
took fasting blood samples and measured height and 
weight using standard protocols. Diabetes was defined as 
a fasting blood glucose level of ≥126 mg/dL, non-fasting 
blood glucose level of ≥200 mg/dL, self-reported 
physician diagnosis of diabetes, or use of antidiabetic 
medication in the past 2 weeks. Hypertension was 
defined as systolic blood pressure ≥140 mm Hg, diastolic 
blood pressure ≥90 mm Hg, or self-reported use of 
antihypertensive medication in the past 2 weeks. History 
of cancer was defined by self-report or incident cancer 
cases found between Visit 1 and time of blood draw 
found through cancer registry and hospital linkage. 
History of coronary heart disease (CHD) was defined as 
self-reported history at baseline or an adjudicated event 
(Myocardial infarction (MI), silent MI, coronary artery 
bypass surgery, or angioplasty) found between Visit 1 
and time of blood draw. 
 
ARIC death ascertainment 
Deaths among cohort participants were identified through 
December 2012 via annual telephone calls and by 
surveillance of local death certificates and obituaries. If a 
participant was lost to telephone follow-up, a National 
Death Index search was conducted. 
 
ARIC DNA methylation quantification 
Genomic DNA was extracted from peripheral blood 
leukocyte samples using the Gentra Puregene Blood Kit 
(Qiagen; Valencia, CA, USA) according to the 
manufacturer’s instructions (https://www.qiagen.com). 
Bisulfite conversion of 1 μg genomic DNA was 
performed using the EZ-96 DNA Methylation Kit (Deep 
Well Format) (Zymo Research; Irvine, CA, USA) 
according to the manufacturer’s instructions 
(https://www.zymoresearch.com). Bisulfite conversion 
efficiency was determined by PCR amplification of 
converted DNA before proceeding with methylation 
analyses on the Illumina platform using Zymo 
Research’s Universal Methylated Human DNA Standard 
and Control Primers. The Illumina Infinium 
HumanMethylation450K Beadchip array (HM450K) 
was used to measure DNA methylation (Illumina, Inc.; 
San Diego, CA, USA). Background subtraction was 
conducted with the GenomeStudio software using built-
in negative control bead types on the array. Positive and 
negative controls and sample replicates were included on 
each 96-well plate assayed. After exclusion of controls, 
replicates, and samples with integrity issues or failed 
bisulfite conversion, a total of 2,841 study participants 
had HM450K data available for further quality control 
(QC) analyses. We removed poor-quality samples with 
pass rate of <99% (i.e., if the sample had at least 1% of 
CpG sites with detection P-value > 0.01 or missing), 
indicative of lower DNA quality or incomplete bisulfite 
conversion, and samples with a possible gender 
mismatch based on evaluation of selected CpG sites on 
the Y chromosome. Additional details have been 
published elsewhere [2 , 3]. 
 
Framingham heart study offspring cohort (FHS) 
 
FHS study participants 
The FHS Offspring Cohort began enrollment in 1971 
and included 5,124 offspring of the FHS original 
cohort as well as spouses of the offspring. Participants 
were eligible for the current study if they attended the 
eighth examination cycle (2005–2008) and consented 
to have their DNA used for genetic research. All 
participants provided written informed consent at the 
time of each examination visit. The study protocol  
was approved by the Institutional Review Board at 
Boston University Medical Center (Boston, MA). FHS 
data are available in dbGaP (accession number: 
phs000724.v2.p9). 
 
FHS death ascertainment 
Deaths among FHS participants that occurred before 
January 1, 2013 were ascertained using multiple 
strategies, including routine contact with participants 
for health history updates, surveillance at the local 
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hospital, obituaries in the local newspaper, and queries 
to the National Death Index. Death certificates, hospital 
and nursing home records before death, and autopsy 
reports were requested. When cause of death was 
undeterminable, the next of kin were interviewed. The 
date and cause of death were reviewed by an endpoint 
panel of three investigators. 
 
FHS DNA methylation quantification 
Peripheral blood samples were collected at the 8th 
examination. Genomic DNA was extracted from buffy 
coats using the Gentra Puregene DNA extraction kit 
(Qiagen) and bisulfite converted using the EZ DNA 
Methylation kit (Zymo Research). DNA methylation 
quantification was conducted in two laboratory batches 
using the Illumina Infinium HumanMethylation450 
array. Methylation beta values were generated using the 
Bioconductor minfi package with background 
correction. Sample exclusion criteria included poor SNP 
matching of control positions, missing rate >1%, 
outliers from multi-dimensional scaling, and sex 
mismatch. In addition, we excluded individuals with 
leukemia and those who received chemotherapy. 
Additional sample exclusions included those with 
mismatches in their reported sex and methylation-
predicted sex as well as methylation-predicted  
tissues that were not blood. Lastly, samples with 
correlation with our reference population of r < 0.80 
were excluded. Predicted sex, tissues, correlation  
with reference population, and DNA methylation-
predicted ages were computed using our online age 
calculator (http://labs.genetics.ucla.edu/horvath/dnamage). 
Background subtraction was applied using the 
preprocessIllumina command in the minfi Bioconductor 
package [4]. In total, 2,635 samples and 443,304 CpG 
probes remained for analysis. 
 
Invecchiare in chianti (InCHIANTI) study 
 
InChianti study participants 
The InCHIANTI Study is a population-based 
prospective cohort study of residents ≥20 years old from 
two areas in the Chianti region of Tuscany, Italy. 
Sampling and data collection procedures have been 
described elsewhere [5]. Briefly, 1,326 participants 
donated a blood sample at baseline (1998–2000), of 
which 784 also donated a blood sample at 9-year 
follow-up (2007–2009). DNA methylation was assayed 
using the Illumina Infinium HumanMethylation450 
platform in DNA samples corresponding to participants 
with sufficient DNA at both baseline and Year  
9 visits (n = 499). All participants provided written 
informed consent to participate in this study. The  
study complied with the Declaration of Helsinki.  
The Italian National Institute of Research and Care on 
Aging Institutional Review Board approved the study 
protocol. 
InChianti death ascertainment 
Vital status was ascertained using data from the 
Tuscany Regional Mortality General Registry. Deaths 
were assessed until December 1, 2014. 
 
InChianti DNA methylation quantification 
Genomic DNA was extracted from buffy coat samples 
using an AutoGen Flex and quantified on a 
Nanodrop1000 spectrophotometer before bisulfite 
conversion. Genomic DNA was bisulfite converted using 
the Zymo EZ-96 DNA Methylation Kit (Zymo Research) 
per the manufacturer’s protocol. CpG methylation status 
of 485, 577 CpG sites was determined using the Illumina 
Infinium HumanMethylation450 BeadChip per the 
manufacturer’s protocol, as previously described [6]. 
Initial data analysis was performed using GenomeStudio 
2011.1 (Model M Version 1.9.0, Illumina Inc.). 
Threshold call rate for inclusion of samples was 95%. 
Quality control of sample handling included comparison 
of clinically reported sex versus sex of the same samples 
determined by analysis of methylation levels of CpG sites 
on the X chromosome [6]. Background subtraction was 
applied using the preprocessIllumina command in the 
minfi Bioconductor package [4]. 
 
Cooperative health research in the region of 
augsburg (KORA) F4 cohort  
 
KORA cohort description 
The KORA study is an independent population-based 
cohort from Augsburg, Southern Germany. Whole 
blood samples of the KORA F4 survey (examination 
2006–2008), a seven-year follow-up study of the 
KORA S4 cohort, were used. Out of 4,621 participants 
for the KORA S4 baseline study, 3,080 participants 
participated in the KORA F4 follow-up study [7]. 
Participants provided written informed consent, and 
the study was approved by the local ethics committee 
(Bayerische Landesärztekammer). For 1,799 subjects, 
methylation data as well as information about  
death ascertainment was available. Before analyses,  
all individuals with a detection P-value > 0.05 for >1% 
of probes were removed (375 individuals). Sex  
checks performed during calculation of DNAmAge 
resulted in the removal of another 167 individuals, 137 
of whom had an “unsure” gender. This left 1,257 
individuals for analysis. At the KORA F4 follow-up 
examination, all individuals completed questionnaires 
and physical examinations conducted by trained  
staff covering demographics, lifestyle, and medical 
history since the KORA S4 examination. Collected 
information included age, sex, years of education, 
smoking status (current regular, current irregular, 
former, never), pack-years, alcohol consumption 
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(g/day), physical activity (active, inactive), diabetes 
status, hypertension status, self-reported cancer 
diagnosis, and body mass index (BMI), among other 
clinical variables [7]. 
 
KORA mortality ascertainment 
The vital status of all F4 participants was ascertained 
through the population registries inside and outside  
the study area in 2011 (cut-off date: December 31, 
2011). Record linkage was based on name, sex, date of 
birth, and address. If the person died, the time and 
location of death was assessed via population 
registries, and a copy of the death certificate was 
obtained from the Regional Health Department. If the 
person moved out of the study area, time of the move 
and information on the new address was typically 
available. Vital status could not be assessed for those 
who had moved to a foreign country or to an unknown 
location in the country. Causes of death were ICD-9 
revision coded. There were a total of 42 deaths, 
including 16 from cardiovascular disease and 17 from 
cancer. 
 
KORA DNA methylation measures 
Whole blood was drawn into serum gel tubes. We 
bisulfite-converted 1 µg of genomic DNA using the EZ-
96 DNA Methylation Kit (Zymo Research) according to 
the manufacturer’s procedure, with the alternative 
incubation conditions recommended when using the 
Illumina Infinium Methylation Assay. Genome-wide 
DNA methylation was analyzed in 1,799 subjects using 
the Illumina Infinium HumanMethylation450 BeadChip 
Array. Raw methylation data were extracted using the 
Illumina Genome Studio (version 2011.1) with the 
methylation module (version 1.9.0). Preprocessing was 
performed with R (version 3.0.1). Probes with signals 
from less than three functional beads and probes with a 
detection P-value > 0.01 were defined as low-
confidence probes. Probes that covered SNPs (MAF in 
Europeans > 5%) were excluded from the data set. A 
color bias adjustment was performed with the R 
package lumi (version 2.12.0) by smooth quantile 
normalization and background correction based on 
negative control probes present on the Infinium 
HumanMethylation BeadChip. This was performed 
separately for the two-color channels and chips. β-
values corresponding to low-confidence probes were set 
to missing. A 95% call rate threshold was applied on 
samples and CpG sites. Beta-mixture quantile 
normalization (BMIQ) was applied by using the R 
package wateRmelon, version 1.0.3. Plate and batch 
effects were investigated by principle component 
analysis and eigenR2 analysis, because KORA F4 
samples were processed on 20 96-well plates across 
nine different batches. 
 
Probes with a detection P > 0.05 for > 1% of samples 
were removed as well as all “ch” and “rs” probes, 
leaving a total of 431, 217 probes for analysis. Although 
raw beta values were used in Dr. Horvath’s online 
calculator to determine cell counts, normalized data was 
used for the final analyses. 
 
To reduce non-biological variability between 
observations, data were normalized using quantile 
normalization on raw signal intensities. Precisely, 
quantile normalization was stratified to six probe 
categories based on probe type and color channel (i.e., 
Infinium I signals from beads targeting methylated CpG 
sites obtained through red and green color channels, 
Infinium I signals from beads targeting unmethylated 
CpG sites obtained through red and green color 
channels, and Infinium II signals obtained through red 
and green color channels [8]) using the R package 
limma, version 3.16.5 [9]. Further, to correct the shift in 
the distribution of methylation values observed for the 
two different assay designs (Infinium I and Infinium II) 
on the BeadChip, BMIQ was applied [10] using the R 
package wateRmelon, version 1.0.3 [11]. 
 
Lothian birth cohorts of 1921 and 1936 (LBC1921 
and LBC1936) 
 
LBC cohort description 
LBC1921 and LBC1936 are two longitudinal studies of 
aging [12, 13] that derive from the Scottish Mental 
Surveys of 1932 and 1947, respectively, when nearly  
all 11-year-old children in Scotland completed a  
test of general cognitive ability [14]. Survivors living in 
the Lothian area of Scotland were recruited in late-life 
at a mean age of 79 years for LBC1921 (n = 550)  
and mean age of 70 years for LBC1936 (n = 1,091). 
Follow-up took place at ages 70, 73, and 76 years in 
LBC1936 and ages 79, 83, 87, and 90 years in 
LBC1921. Collected data include genetic information, 
longitudinal epigenetic information, longitudinal brain 
imaging (LBC1936), numerous blood biomarkers, and 
anthropomorphic and lifestyle measures. Post-QC, 
DNA methylation data were available for 920 LBC1936 
participants at age 70 years and for 446 LBC1921 
participants at age 79 years. At each in-person visit, 
participants completed questionnaires regarding 
demography, lifestyle, and medical history. They 
reported chronological age, years of education, smoking 
status (never, former, current), pack-years consumption 
(continuous), alcohol consumption (light, moderate, and 
heavy drinkers), self-reported type 2 diabetes, cancer, 
and hypertension. BMI was computed from 
anthropometric measures. Participants were asked to 
remove their shoes before a SECA stadiometer was 
used to assess height in centimeters. Weight (after 
removing shoes and outer clothing) was measured in 
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kilograms using a digital readout from electronic SECA 
scales. 
LBC mortality ascertainment 
For both LBC1921 and LBC1936, mortality status was 
obtained via data linkage from the National Health 
Service Central Register, provided by the General 
Register Office for Scotland (now National Records of 
Scotland). Participant deaths and cause of death are 
routinely flagged to the research team about every 12 
weeks. The last update available for the current project 
was 26th November 2014. 
 
LBC DNA methylation measures 
Detailed information about collection and QC steps on 
LBC methylation data have been reported previously 
[12, 15]. Briefly, the Illumina Infinium 
HumanMethylation450 BeadChip was used to measure 
DNA methylation in whole blood of consenting 
participants. Background correction was performed, and 
QC was used to remove probes with a low detection 
rate, low quality (manual inspection), and low call rate 
as well as samples with a poor match between 
genotypes and SNP control probes or incorrect 
predicted sex. Additional QC was performed to remove 
samples and probes in which >1% of probes or samples, 
respectively, had a detection P > 0.05. The working set 
included 442, 227 CpG probes.  
 
Normative aging study (NAS) 
 
NAS cohort description 
The ongoing longitudinal US Department of Veterans 
Affairs NAS was established in 1963 and included men 
21–80 years old and free of known chronic medical 
conditions at entry [16]. Participants were invited to 
medical examinations every three to five years. At each 
visit, men provided information on medical history, 
lifestyle, and demographic factors and underwent 
physical examinations and laboratory tests. DNA 
samples were collected from 675 active participants 
between 1999–2007 [16]. We excluded participants 
who were non-white or who reported leukemia at the 
time of DNA extraction, leaving a total of 646 
individuals with a single observation each. Participants 
provided written informed consent at each visit. The 
NAS study was approved by the institutional review 
boards of participating institutions. At each in-person 
visit, participants completed questionnaires regarding 
demography, lifestyle, and medical history. They 
reported chronological age, years of education, smoking 
status (never, former, current), pack-years consumption 
(continuous), alcohol consumption (<2, ≥2 drinks/day), 
physical activity (<12, 12–30, ≥30 metabolic equivalent 
hours [MET-h] per week), type 2 diabetes (self-reported 
diagnosis and/or use of diabetes medications), diagnosis 
of CHD (validated on medical records, ECG, and 
physician exams), diagnosis of malignant cancer in the 
five years prior the visit (diagnosed with ICD-9 code). 
High blood pressure was defined as antihypertensive 
medication use, systolic blood pressure ≥140 mmHg, or 
diastolic blood pressure ≥90 mmHg at study visit. BMI 
was computed from anthropometric measures, 
performed with participants in undershorts and  
socks [17]. 
 
NAS mortality ascertainment 
Official death certificates were obtained for decedents 
from the appropriate state health departments and were 
reviewed by a physician. An experienced research nurse 
coded the cause of death using ICD-9. Both participant 
deaths and causes of death were routinely updated by 
the research team, and the last update available was 
December 31, 2013 [12]. 
 
NAS DNA methylation measures 
DNA was extracted from buffy coats using the QIAamp 
DNA Blood Kit (Qiagen). We used 500 ng of DNA for 
bisulfite conversion using the EZ-96 DNA Methylation 
Kit (Zymo Research). To reduce chip and plate effects, 
we used a two-stage age-stratified algorithm to 
randomize samples and ensure similar age distributions 
across chips and plates; 12 samples that were sampled 
across all age quartiles were randomized to each chip, 
and then chips were randomized to plates (8 
chips/plate).  
 
QC analysis was performed to remove samples and 
probes, where >1% of probes or samples, respectively, 
had a detection P > 0.05. Remaining samples were 
preprocessed using the Illumina-type background 
correction [18] and normalized with dye-bias [19] and 
BMIQ [20] adjustments, which were used to generate 
beta methylation values. The working set included 477, 
928 CpG probes. DNA methylation age was computed 
using the Horvath calculator from background-corrected 
methylation data, and QC analysis was performed only 
on samples, leaving 485, 512 CpG and CpH probes in 
the working set. 
 
TwinsUK 
 
TwinsUK study participants 
The TwinsUK cohort was established in 1992 and 
recruited both monozygotic and dizygotic same-sex 
twins in the United Kingdom. The majority of 
participants are female, Caucasian, and mostly disease-
free at time of ascertainment. There are >13, 000 twin 
participants in the cohort, of which 805 were included 
in the current study. Whole blood samples were 
collected during participants’ clinical visits, along with 
questionnaire data on phenotype and lifestyle factors. 
All subjects provided written informed consent [21]. 
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Information on physical activity, smoking pack-years, 
plate number, and chip position number were not 
available for subjects in the TwinsUK dataset and 
therefore were not adjusted as covariates in all analyses. 
 
TwinsUK death ascertainment 
Mortality data were collected using two approaches: 1) 
during routine contact for standard clinical visits in 
TwinsUK, and 2) using queries to the National Death 
Register. Date and cause of death were recorded. 
 
TwinsUK DNA methylation quantification 
DNA samples were extracted from whole blood using 
the DNeasy kit (Qiagen). DNA was bisulfite converted 
using the EZ DNA methylation kit (Zymo Research). 
Methylation levels were profiled using the Illumina 
Infinium HumanMethylation450 array, and methylation 
betas were generated using the R package minfi with 
background correction. Raw beta levels were subjected 
to BMIQ dilation to correct for technical effects. Probe 
exclusion criteria included probes that mapped to 
multiple locations in the reference sequence and probes 
in which >1% of subjects had detection P > 0.05. 
Individuals with >5% missing probes, with mismatched 
sex, and with mismatched genotypes were also excluded. 
Methylation-predicted sex, methylation-predicted  
blood cell types, correlations with the reference 
population, and DNA methylation-predicted age were 
computed using the online epigenetic age calculator 
(http://labs.genetics.ucla.edu/horvath/dnamage). 
 
Women’s health initiative–broad agency 
announcement 23 (WHI-BAA23)  
 
WHI-BAA23 cohort description 
Subjects included a subsample of participants of the 
WHI study, a national study that began in 1993 and 
enrolled postmenopausal women 50–79 years of age 
into one of three randomized clinical trials. Women 
were selected from one of two WHI large sub-cohorts 
that had previously undergone genome-wide genotyping 
as well as profiling for 7 cardiovascular disease-related 
biomarkers, including total cholesterol, high-density 
lipoprotein, low-density lipoprotein, triglycerides, C-
reactive protein (CRP), creatinine, insulin, and glucose 
through two core WHI ancillary studies [22]. The first 
cohort is the WHI SNP Health Association Resource 
(SHARe) cohort of minorities that includes >8,000 
African American (AA) women and >3,500 Hispanic 
women. Women were genotyped through the WHI  
core study M5-SHARe (www.whi.org/researchers/data/ 
WHIStudies/StudySites/M5) and underwent biomarker 
profiling through WHI Core study W54-SHARe 
(...data/WHIStudies/StudySites/W54). The second cohort 
consists of a combination of European Americans  
(EA) from two hormonal therapy trials selected  
for GWAS and biomarkers in core studies W58 (.../ 
data /WHIStudies/StudySites/W58) and W63 (.../data/ 
WHIStudies/StudySites/W63). From these two cohorts, 
two sample sets were formed. Sample Set 1 is a sample 
set of 637 CHD cases and 631 non-CHD cases as of Sept 
30, 2010. Sample Set 2 is a non-overlapping sample of 
432 cases of CHD and 472 non-CHD cases as of 
September 17, 2012. The ethnic groups differed in terms 
of age distribution, as Caucasian women tended to be 
older. We acknowledge a potential for selection bias 
using the above-described sampling scheme in WHI but 
suspect that if such bias is present, it is minimal. First, 
selection bias is introduced by restricting our methylation 
profiling at baseline to women with GWAS and 
biomarker data from baseline as well, given the 
requirement that these subjects must have signed the 
WHI supplemental consent for broad sharing of genetic 
data in 2005. However, we believe that selection bias at 
this stage is minimized by inclusion of subjects who died 
between time of start of the WHI study and time of 
supplemental consent in 2005, which excluded only 
~6%–8% of all WHI participants. Subjects unable or 
unwilling to sign consent in 2005 may not represent a 
random subset of all participants who survived to 2005. 
Second, some selection bias may also occur if similar 
gross differences exist in the characteristics of 
participants who consented to be followed in the two 
WHI extension studies beginning in 2005 and 2010 
compared to non-participants at each stage. We believe 
these selection biases, if present, have minimal effects on 
our effect estimates. Data are available from this page: 
https://www.whi.org/researchers/Stories/June%202015
%20WHI%20Investigators’%20Datasets%20Released.
aspx, as well as https://www.whi.org/researchers/data/ 
Documents/WHI%20Data%20Preparation%20and%20
Use.pdf 
 
WHI-BAA23 death ascertainment 
We used the variable "DEATHALL" from form 
124/120 that incorporated any report of death (as of 
August 2015).  
 
WHI-BAA23 DNA methylation quantification 
In brief, bisulfite conversion using the Zymo EZ DNA 
Methylation Kit (Zymo Research) as well as subsequent 
hybridization of the Illumina HumanMethylation450k 
Bead Chip and scanning (iScan, Illumina) were 
performed according to the manufacturer’s protocols by 
applying standard settings. DNA methylation levels  
(β values) were determined by calculating the ratio of 
intensities between methylated (signal A) and un-
methylated (signal B) sites. Specifically, β value was 
calculated from the intensity of methylated (M 
corresponding to signal A) and un-methylated  
(U corresponding to signal B) sites, as the ratio of 
fluorescent signals β = Max(M,0)/[Max(M,0)+Max 
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(U,0)+100]. Thus, β values range from 0 (completely 
un-methylated) to 1 (completely methylated). 
Women’s health initiative—epigenetic mechanisms 
of PM-Mediated CVD risk (WHI-EMPC) 
 
WHI-EMPC cohort description 
WHI-EMPC is an ancillary study of epigenetic 
mechanisms underlying associations between ambient 
particulate matter (PM) air pollution and cardiovascular 
disease in the WHI clinical trials (CT) cohort. It is 
funded by the National Institute of Environmental 
Health Sciences (R01-ES020836).  
 
The WHI-EMPC study population is a stratified, random 
sample of 2,200 WHI CT participants who were 
examined in 1993–2001; had available buffy coats, core 
analytes, electrocardiograms, and ambient concentrations 
of PM; and were not taking anti-arrhythmic medications 
at the time. 
 
As such, WHI-EMPC is representative of the larger, 
multiethnic WHI CT population from which it was 
sampled: 68 ,132 participants aged 50–79 years who 
were randomized to hormone therapy, calcium/vitamin 
D supplementation, and/or dietary modification in 40 
U.S. clinical centers at baseline exam (1993–1998) and 
re-examined in the fasting state one, three, six, and nine 
years later [23, 24]. During participant visits, data on 
age, race/ethnicity, education, smoking status (current, 
former, never), pack-years of smoking, alcohol 
consumption (drinks per week), recreational physical 
activity (MET-hours/week), weight/height/BMI, 
systolic and diastolic blood pressure, medication use, 
CHD, type 2 diabetes, and cancer diagnosis were 
obtained.  
 
Hypertension status was based on systolic blood 
pressure ≥140 mmHg or diastolic blood pressure 
≥90 mmHg or antihypertensive medication use 
(angiotensin converting enzyme inhibitors, angiotensin 
II receptor antagonists, beta blockers, calcium  
channel blockers, thiazides). CHD was defined by a 
history of myocardial infarction (acute, hospitalized, 
definite or probable events supported by cardiac  
pain, electrocardiogram, and biomarker data) or 
revascularization procedure (coronary artery bypass 
graft, percutaneous coronary angioplasty, stent) and 
was self-reported at baseline and confirmed by 
physician-review, classification, and local/central 
adjudication of medical records during follow-up. 
Type 2 diabetes was defined by a self-reported  
history of physician-treated diabetes, fasting glucose 
≥126 mg/dL, non-fasting glucose ≥200 mg/dL,  
or anti-diabetic medication use. Cancer was defined by 
a diagnosis of any cancer, excluding leukemia  
and other hematologic malignancies (Hodgkin’s 
lymphoma, non-Hodgkin’s lymphoma, multiple 
myeloma).  
Current analyses involve information collected at the 
first available visit with available DNA methylation 
data and stratification by race/ethnicity [European 
(WHI-EMPC-EA) and African American (WHI-EMPC-
AA) ancestries]. 
 
WHI-EMPC mortality ascertainment 
All-cause mortality and sub-classification of the 
underlying cause of death to cardiovascular or cancer 
mortality were based on WHI physician review of death 
certificates, medical records, and autopsy reports. 
Cardiovascular disease mortality was defined as death 
due to definite or possible CHD, cerebrovascular 
disease, or other or unknown cardiovascular disease. 
Cancer mortality was defined as death due to any 
cancer. Participants affected by leukemia or other 
hematologic malignancies (i.e., Hodgkin’s lymphoma, 
non-Hodgkin’s lymphoma, multiple myeloma) were 
excluded due to known effects on red cell, white cell, 
and platelet counts.  
 
WHI-EMPC DNA methylation quantification 
Genome-wide DNA methylation at CpG sites was 
measured using the Illumina 450K Infinium 
Methylation BeadChip, quantitatively represented by 
beta (percentage of methylated cytosines over the sum 
of methylated and unmethylated cytosines) and quality-
controlled using the following filters: detection P > 0.01 
in >10% of samples, detection P > 0.01 or missing in 
>1% of probes, and probes with a coefficient of 
variation <5%, yielding values of beta at 293,171 sites. 
DNA methylation data were normalized using BMIQ 
[25] and stage-adjusted using ComBat [10]. Modeled 
epigenome-wide associations also adjusted for cell 
subtype proportions (CD8-T, CD4-T, B cell, natural 
killer, monocyte, and granulocyte) [26] and for technical 
covariates, including plate, chip, row, and column.  
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Supplementary Figures 
 
 
 
 
Supplementary Figure 1. Sensitivity analysis comparing hazard ratios of the fully-adjusted meta-analysis, including all 
cohorts, all excluding ARIC, or all excluding WHI-BAA23. 
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Supplementary Figure 2. (A) All-cause mortality association of 57 out of 58 CpGs identified with mortality in Zhang et al. (black dots) and 
all-cause mortality association of the same CpGs in the pooled meta-analysis (white dots with 95% confidence intervals). (B) Association of 
methylation levels of 57 out of 58 CpGs identified with mortality in Zhang et al. and our FDR-significant CpGs in all cohorts. 
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Supplementary Figure 3. (A) Methylation quantitative trait loci (meQTL) analysis and (B) expression quantitative quantitative trait 
methylation (eQTM) analysis in KORA. 
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Supplementary Tables 
 
Please browse Full Text version to see the data of Supplementary Tables 1, 2, 6, 10, 12, 17. 
 
Supplementary Table 1. Covariates included in the analysis of each cohort (*variables that differ across cohorts due 
to type of cutoff used in data collection) SD = standard deviation; CHD = coronary heart disease. 
Supplementary Table 2. CpG loci where blood DNA methylation was associated (FDR<0.05) with all-cause mortality 
in fixed-effect meta-analysis from the basic model (i.e., age, gender, technical covariates, and white cell subtypes ). 
Supplementary Table 3. CpG loci where blood DNA methylation was associated (FDR<0.05) with all-cause mortality 
in the fixed-effect meta-analysis from the fully adjusted model. 
Probe name CHR 
Distance 
to nearest 
gene (bp) 
Nearest 
gene  
(10 Mp)a 
Gene 
group 
Relation 
to CpG 
Island 
HRb 95% CI p 
Mean 
methylation 
level 
Bonferroni 
significance 
FDR-
significant 
in basic 
model 
Methylation 
level 
(Mean±SD) 
cg17086398 1 0 SERINC2 Body 
 
1.25 (1.15;1.36) 4.86E-07 0.29   1 0.29 ± 0.06 
cg14866069 4 579 BMPR1B 
  
0.66 (0.56;0.78) 4.85E-07 0.85   
 
0.85 ± 0.05 
cg23666362 4 516 MIR1973 TSS1500 
 
0.69 (0.59;0.8) 8.00E-07 0.82   
 
0.81 ± 0.04 
cg12619262 7 6276 CHST12 
  
1.26 (1.16;1.37) 1.76E-07 0.75   
 
0.75 ± 0.07 
cg20045320 11 116 IFITM3 
 
S_Shore 0.85 (0.8;0.9) 4.06E-09 0.54 1 1 0.54 ± 0.09 
cg07677157 12 
 
NAa 
  
0.79 (0.72;0.86) 2.00E-07 0.16   1 0.18 ± 0.06 
cg07839457 16 435 NLRC5 TSS1500 N_Shore 0.87 (0.84;0.91) 2.40E-09 0.46 1 1 0.45 ± 0.11 
cg09615688 16 
 
NAa 
  
0.53 (0.41;0.68) 9.32E-07 0.91   1 0.90 ± 0.03 
cg18424841 20   NAa   Island 1.2 (1.13;1.28) 2.80E-08 0.7 1   0.69 ± 0.09 
aNearest gene was far more than 10 Mp. 
bEffect estimates represent hazard ratio per 10% increase in DNA methylation. CHR = chromosome; HR = hazard ratio; 95% CI 
= 95% confidence interval; p = p-value; SD = standard deviation. 
 
Supplementary Table 4. Hazard ratios for FDR-significant fully-adjusted CpGs in basic and fully adjusted models CHR 
= chromosome; HR = hazard ratio; 95% CI = 95% confidence interval; p = p-value; SD = standard deviation. 
Probe name CHR 
Fully adjusted model Basic model 
HR 95% CI p HR 95% CI p 
cg17086398 1 1.25 (1.15; 1.36) 4.86E-07 1.37 (1.28; 1.47) 5.32E-20 
cg14866069 4 0.66 (0.56; 0.78) 4.85E-07 0.84 (0.75; 0.94) 2.21E-03 
cg23666362 4 0.69 (0.59; 0.8) 8.04E-07 0.81 (0.72; 0.9) 2.02E-04 
cg12619262 7 1.26 (1.15; 1.38) 1.76E-07 1.13 (1.05; 1.21) 6.77E-04 
cg20045320 11 0.85 (0.80; 0.90) 4.06E-09 0.82 (0.78; 0.86) 2.61E-16 
cg07677157 12 0.79 (0.72; 0.86) 2.00E-07 0.78 (0.72; 0.84) 1.31E-10 
cg07839457 16 0.87 (0.84; 0.91) 2.40E-09 0.88 (0.85; 0.92) 3.40E-11 
cg09615688 16 0.53 (0.41; 0.68) 9.32E-07 0.60 (0.51; 0.72) 8.96E-09 
cg18424841 20 1.20 (1.13; 1.28) 2.80E-08 1.10 (1.05; 1.15) 2.00E-04 
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Supplementary Table 5. Summary of models. 
Cohorts Model used 
Maximum # 
probes 
considered 
Basic model Fully adjusted model 
Lambda 
FDR-
significant 
CpGs 
Lambda 
FDR-
significant 
CpGs 
ARIC Cox Regression 406712 2.46 226 1.63 5 
FHS Study 1 Cox Regressionb 417934 0.94 3 1.04 0 
FHS Study 2 Cox Regressionb 407580 1.32 17 1.16 1 
InChianti Cox Regression 407179 1.41 0 1.44 0 
KORA Cox Regressiona 330133 0.96 4 0.94 0 
LBC 1921 Cox Regression 393529 1.15 0 1.22 0 
LBC 1936 Cox Regression 385450 1.04 0 1 0 
NAS Cox Regression 395005 0.86 0 0.9 0 
TwinsUK Cox Regression a,c 426,120 1.02 0 0.98 0 
WHI-BAA23 Cox Regression 419176 1.7 14 2.02 1 
WHI-EMPC-EA Cox Regressiond 250537 1.23 9 0.93 0 
WHI-EMPC-AA Cox Regressiond 218018 0.92 0 1.09 0 
All cohorts Fixed effect meta-analysise 426724 1.12 257 0.94 9 
aCohort used as predictor of residuals from linear regression analysis between each probe and sets of covariates. 
bCohort included cluster for family structure. 
cCohort included random intercepts for zygosity and family structure. 
dCohort considered only CpGs with coefficient of variation >5%. 
eAnalysis of each CpG site included results of at least three cohorts. 
Basic model: adjusted for age (categories), gender, technical variables, white blood cell count.  
Fully adjusted model: adjusted for age (categories), gender, technical variables, white blood cell count, education level, 
physical activity, smoking status, smoking consumption (packyears), body mass index (categories), alcohol consumption, prior 
coronary heart disease (y/n), diabetes (y/n), hypertension (y/n), cancer (y/n). 
 
Supplementary Table 6. I2 measure of heterogeneity from random-effect meta-analysis in each FDR-significant basic-
adjusted CpG. 
 
Supplementary Table 7. I2 measure of heterogeneity from random-effect meta-analysis in each FDR-significant fully-
adjusted CpG. 
Probe name CHR 
Distance to nearest 
gene (bp) 
Nearest gene 
Gene group 
Relation to 
CpG island 
I2 
 (10 Mp)a  
cg17086398 1 0 SERINC2 Body 
 
0.02 
cg14866069 4 579 BMPR1B 
  
0 
cg23666362 4 516 MIR1973 TSS1500 
 
0.01 
cg12619262 7 6276 CHST12 
  
0.01 
cg20045320 11 116 IFITM3 
 
S_Shore 53.53 
cg07677157 12 
 
NAa 
  
0 
cg07839457 16 435 NLRC5 TSS1500 N_Shore 0 
cg09615688 16 
 
NAa 
  
29.9 
cg18424841 20   NAa   Island 2.65 
aNearest gene was far more than 10 Mp. 
bEffect estimates represent hazard ratio per 10% increase in DNA methylation. 
CHR = chromosome; HR = hazard ratio; 95% CI = 95% confidence interval; p = p-value; SD = standard deviation. 
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Supplementary Table 8. FDR-significant fully-adjusted CpGs in fixed effect meta-analysis with exclusion of ARIC. 
Probe name CHR 
Distance to 
nearest gene 
(bp) 
Nearest gene  
(10 Mp)a 
Gene group 
Relation to 
CpG island 
HR 95% CI p 
Mean DNA 
methylation 
level 
cg17086398 1 0 SERINC2 Body 
 
1.25 (1.11; 1.41) 3.80E-04 0.29 
cg14866069 4 579 BMPR1B 
  
0.65 (0.52; 0.8) 6.86E-05 0.84 
cg23666362 4 516 MIR1973 TSS1500 
 
0.74 (0.62; 0.89) 1.35E-03 0.8 
cg12619262 7 6276 CHST12 
  
1.27 (1.12; 1.45) 3.31E-04 0.74 
cg20045320 11 116 IFITM3 
 
S_Shore 0.88 (0.82; 0.95) 8.76E-04 0.54 
cg07677157 12 
 
NAa 
  
0.76 (0.66; 0.87) 4.78E-05 0.19 
cg07839457 16 435 NLRC5 TSS1500 N_Shore 0.86 (0.81; 0.92) 3.70E-06 0.45 
cg09615688 16 
 
NAa 
  
0.53 (0.41; 0.68) 9.32E-07 0.89 
cg18424841 20   NAa   Island 1.17 (1.08; 1.27) 1.90E-04 0.68 
aNearest gene was far more than 10 Mp. 
bEffect estimates represent hazard ratio per 10% increase in DNA methylation. 
CHR = chromosome; HR = hazard ratio; 95% CI = 95% confidence interval; p = p-value; SD = standard deviation. 
 
Supplementary Table 9. FDR-significant fully-adjusted CpGs in fixed effect meta-analysis with exclusion of WHI-
Study 1. 
Probe name CHR 
Distance to 
nearest 
gene (bp) 
Nearest gene 
(10 Mp)a 
Gene group 
Relation to 
CpG island 
HR 95% CI p 
Mean DNA 
methylation 
level 
cg17086398 1 0 SERINC2 Body  1.26 (1.15; 1.38) 4.30E-07 0.29 
cg14866069 4 579 BMPR1B   0.67 (0.56; 0.79) 2.23E-06 0.85 
cg23666362 4 516 MIR1973 TSS1500  0.68 (0.58; 0.79) 1.16E-06 0.81 
cg12619262 7 6276 CHST12   1.23 (1.13; 1.35) 5.93E-06 0.74 
cg20045320 11 116 IFITM3  S_Shore 0.86 (0.81; 0.91) 2.94E-07 0.54 
cg07677157 12  NAa   0.79 (0.72; 0.87) 2.57E-06 0.17 
cg07839457 16 435 NLRC5 TSS1500 N_Shore 0.87 (0.84; 0.92) 1.30E-08 0.45 
cg09615688 16  NAa   0.53 (0.4; 0.69) 2.57E-06 0.9 
cg18424841 20  NAa  Island 1.21 (1.13; 1.3) 1.53E-08 0.69 
aNearest gene was far more than 10 Mp. 
bEffect estimates represent hazard ratio per 10% increase in DNA methylation. 
CHR = chromosome; HR = hazard ratio; 95% CI = 95% confidence interval; p = p-value; SD = standard deviation. 
 
Supplementary Table 10. Fixed effects meta-analysis results on incident coronary heart disease from the CHARGE 
Consortium. 
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Supplementary Table 11. Miettinen’s population attributable factor for NAS, WHI-EMPC-EA, and WHI-EMPC-AA as 
well as weighted combination (average). 
CpG NAS WHI-EMPC-EA WHI-EMPC-AA Mean SD 
cg17086398 6.47 5.55 3.57 5.20 1.21 
cg14866069 -17.20 -6.77 -20.09 -14.69 5.72 
cg23666362 -15.19 . . -15.19 0.00 
cg12619262 7.33 -1.18 4.27 3.48 3.52 
cg20045320 -5.34 -0.67 -1.42 -2.48 2.05 
cg07677157 -7.29 -9.43 -27.86 -14.86 9.23 
cg07839457 -4.08 -3.07 -3.43 -3.53 0.42 
cg09615688 . 1.43 . 1.43 0.00 
cg18424841 5.97 3.51 4.91 4.80 1.01 
 
Supplementary Table 12. Standardized betas identifying the linear relationship between FDR-significant fully-
adjusted CpGs and conventional risk factors. 
 
Supplementary Table 13. Standardized betas identifying the linear relationship between FDR-significant fully-
adjusted CpGs and epigenetic aging clock in NAS, after adjusting all conventional risk factors. 
Epigenetic age 
cg17086398 cg14866069 cg23666362 cg12619262 cg20045320 cg07677157 cg07839457 cg18424841 
Est (p) Est (p) Est (p) Est (p) Est (p) Est (p) Est (p) Est (p) 
Horvath epigenetic aging clock (years) -0.09(0.1) 0.03(0.51) 0.01(0.78) 0.23(0) -0.27(0) -0.13(0.02) -0.19(0) 0.11(0.03) 
Hannum epigenetic aging clock (years) -0.07(0.24) -0.17(0) -0.14(0.01) 0.36(0) -0.08(0.23) -0.06(0.34) -0.28(0) 0.18(0) 
Weidener epigenetic aging clock (years) 0.02(0.69) -0.03(0.39) -0.01(0.72) 0.08(0.1) -0.07(0.11) -0.04(0.46) -0.04(0.41) 0.06(0.16) 
PhenoAge (years) -0.04 (0.5) -0.11 (0.01) -0.11 (0.02) 0.02 (0.76) -0.27 (0) 0 (0.93) -0.19 (0) 0.13 (0.01) 
Mortality risk score 0.04 (0.44) -0.22 (0) -0.19 (0) 0.34 (0) -0.19 (0) -0.49 (0) -0.03 (0.57) -0.07 (0.22) 
Est = estimate; p = p-value. 
 
Supplementary Table 14. Association with all-cause mortality and DNA methylation levels at FDR-significant CpGs, 
adjusting for epigenetic acceleration ages in the Normative Aging Study (NAS). 
Association with 
mortality 
CpG alone 
CpG + DNAmAge acceleration CpG + PhenoAge acceleration 
CpG 
DNAmAge 
acceleration 
CpG 
PhenoAge 
acceleration 
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
cg17086398 1.03 (0.83-1.27) 1.02 (0.82-1.27) 0.99 (0.97-1.03) 1.02 (0.82-1.26) 1.01 (0.98-1.03) 
cg14866069 0.44 (0.30-0.70) 0.44 (0.30-0.69) 0.99 (0.97-1.02) 0.44 (0.28-0.70) 1.00 (0.98-1.03) 
cg23666362 0.80 (0.52-1.23) 0.80 (0.52-1.23) 1.00 (0.97-1.03) 0.78 (0.50-1.20) 1.01 (0.99-1.03) 
cg12619262 1.08 (0.88-1.33) 1.09 (0.89-1.34) 0.99 (0.97-1.02) 1.09 (0.88-1.33) 1.01 (0.98-1.03) 
cg20045320 0.94 (0.81-1.09) 0.93 (0.81-1.08) 0.99 (0.97-1.02) 0.94 (0.82-1.09) 1.01 (0.98-1.03) 
cg07677157 0.70 (0.52-0.94) 0.70 (0.52-0.94) 0.99 (0.97-1.02) 0.70 (0.52-0.94) 1.00 (0.98-1.03) 
cg07839457 0.87 (0.78-0.97) 0.86 (0.77-0.96) 0.99 (0.97-1.02) 0.87 (0.78-0.97) 1.01 (0.98-1.03) 
cg18424841 1.09 (0.94-1.26) 1.07 (0.92-1.25) 1.00 (0.97-1.02) 1.09 (0.94-1.26) 1.01 (0.98-1.03) 
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Supplementary Table 15. Association with all-cause mortality and DNA methylation levels at FDR-significant CpGs 
adjusting for mortality risk score in the Normative Aging Study (NAS). 
Association with mortality 
CpG alone 
CpG + mortality risk score 
CpG Mortality risk score 
HR (95% CI) HR (95% CI) HR (95% CI) 
cg17086398 1.03 (0.83-1.27) 1.12 (0.89-1.41) 1.68 (1.15-2.47) 
cg14866069 0.44 (0.30-0.70) 0.45 (0.28-0.74) 1.39 (0.95-2.04) 
cg23666362 0.80 (0.52-1.23) 0.87 (0.55-1.36) 1.55 (1.06-2.27) 
cg12619262 1.08 (0.88-1.33) 1.01 (0.81 – 1.26) 1.60 (1.08-2.35) 
cg20045320 0.94 (0.81-1.09) 0.96 (0.82-1.12) 1.57 (1.08-2.28) 
cg07677157 0.70 (0.52-0.94) 0.74 (0.55-1.01) 1.46 (1.00-2.14) 
cg07839457 0.87 (0.78-0.97) 0.88 (0.79-0.99) 1.51 (1.05-2.18) 
cg18424841 1.09 (0.94-1.26) 1.07 (0.92-1.24) 1.59 (1.10-2.30) 
 
Supplementary Table 16. Enrichment analysis for genes identified in GWAS of death-related factors. 
Disease Gene Enrichment p-value Enrichment_FDR 
Alcohol dependence SERINC2 0.002 0.004 
HDL cholesterol NLRC5 0.022 0.022 
p = p-value; FDR = false discovery rate. 
 
Supplementary Table 17. KEGG pathways for FDR-significant CpGs in the basic model. 
 
Supplementary Table 18. Pathways analysis with DAVID. 
Gene  Official gene name Diseases Disease class p 
NLRC5 NLR family CARD 
domain containing 5 
Chronic renal failure, kidney failure, chronic 
coronary disease, erythrocyte count, type 2 
diabetes 
CARDIOVASCULAR, 
HEMATOLOGICAL, 
METABOLIC, RENAL 
>0.05 
BMPR1B Bone morphogenetic 
protein receptor type 
1B 
Alcoholism, attention deficit disorder with 
hyperactivity, bone mineral density, cleft lip, cleft 
palate, hypertension, increased ovulation rate, 
juvenile polyposis, obesity, premature ovarian 
failure, polycystic ovarian syndrome, primary 
ovarian insufficiency, puberty (delayed), puberty 
(precocious), thrombophilia, tobacco use disorder 
CARDIOVASCULAR, 
CHEMDEPENDENCY, 
DEVELOPMENTAL, 
METABOLIC, 
OTHER, PSYCH, 
REPRODUCTION 
>0.05 
CHST12 Carbohydrate 
sulfotransferase 12 
Malaria, placenta diseases, pregnancy 
complications, parasitic 
INFECTION >0.05 
IFITM3 Interferon induced 
transmembrane 
protein 3 
Ulcerative colitis IMMUNE >0.05 
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Supplementary Table 19. Association between fully-adjusted FDR-significant CpGs and SNPs (meQTL analysis) in 
KORA. 
Fully-adjusted FDR-significant CpGs SNP 
Est. SE p 
Name CHR Position Name CHR Position 
cg09615688 16 80982506 rs8052401 16 80983487 -0.005 0.001 3.81E-08 
cg18424841 20 61315444 rs2427380 20 61314740 0.020 0.002 2.27E-16 
cg18424841 20 61315444 rs2427381 20 61314785 0.014 0.003 2.50E-08 
cg18424841 20 61315444 rs118042746 20 61314972 -0.039 0.007 2.47E-09 
cg18424841 20 61315444 rs6010861 20 61315002 0.024 0.003 9.67E-17 
cg18424841 20 61315444 rs2427382 20 61315199 0.015 0.002 6.91E-10 
cg18424841 20 61315444 rs6062825 20 61315436 0.016 0.003 2.37E-06 
cg18424841 20 61315444 rs4809278 20 61315545 0.020 0.002 6.81E-16 
cg18424841 20 61315444 rs6122386 20 61316386 0.015 0.002 6.20E-10 
CHR = chromosome; Est = estimate; SE = standard error; p = p-value. 
 
Supplementary Table 20. Association between fully-adjusted FDR-significant CpGs and gene expression (eQTM 
analysis) in KORA. 
Probe name CHR 
Distance to 
nearest gene 
(bp) 
Nearest gene 
Influenced 
gene name 
Est SE p FDR 
cg17086398 1 0 SERINC2 MARCKSL1 -0.75 0.20 1.77E-04 5.92E-03 
cg20045320 11 116 IFITM3 IFITM3 -3.45 0.43 3.19E-15 7.48E-13 
cg20045320 11 116 IFITM3 IRF7 -0.76 0.17 8.78E-06 4.11E-04 
cg07839457 16 435 NLRC5 MT2A -1.48 0.24 7.92E-10 9.27E-08 
cg07839457 16 435 NLRC5 MT1E -0.66 0.19 5.17E-04 1.34E-02 
cg07839457 16 435 NLRC5 MT1A -1.11 0.20 1.98E-08 1.54E-06 
cg07839457 16 435 NLRC5 MT1G -0.25 0.07 6.70E-04 1.57E-02 
cg07839457 16 435 NLRC5 MT1IP -0.39 0.10 1.64E-04 5.92E-03 
cg07839457 16 435 NLRC5 NLRC5 -0.70 0.15 3.67E-06 2.15E-04 
CHR = chromosome; Est = estimate; SE = standard error; p = p-value; FDR = false discovery rate. 
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Supplementary Table 21. Causal association between coronary heart disease, kidney function (serum creatinine), 
and methylation at FDR-significant CpGs in KORA and ARIES. 
D
is
e
a
se
 
Methylation locus OR 95% LCI 95% UCI P methQTL cohort N SNPs MR method 
cg09615688 1.508 1.0199 2.2297 0.0395 KORA 1 Wald ratio 
cg18424841  1.0058 0.9994 1.0122 0.0743 ARIES 1 Wald ratio 
cg18424841 0.8506 0.7292 0.9922 0.0944 KORA 7 MR Egger 
cg18424841 1.01 0.9218 1.1068 0.8375 KORA 7 Weighted mode 
cg18424841 1.0007 0.9399 1.0656 0.9814 KORA 7 Weighted median 
cg09615688 0.8816 0.7449 1.0435 0.1429 KORA 1 Wald ratio 
cg18424841 1.0014 0.9989 1.0039 0.2771 ARIES 1 Wald ratio 
cg18424841 0.9279 0.8297 1.0377 0.4148 KORA 3 MR Egger 
cg18424841 0.9903 0.957 1.0246 0.6305 KORA 3 Weighted mode 
cg18424841 0.9939 0.9637 1.025 0.6969 KORA 3 Weighted median 
Odds ratio (OR), lower 95% confidence interval (LCI), and upper 95% confidence interval (UCI) given per 10% higher 
methylation. Associations for coronary heart disease taken from (PMC4589895) and association for serum creatinine taken 
from (PMC4735748). Associations for ARIES methQTLs extracted from MR-base (PMC5976434) using middle age estimates 
for methQTLs from ARIES cohort (PMC4818469). MR = mendelian randomization; N SNPs = number of SNPs (instruments) 
used for the MR analyses; P = p-value. 
 
Supplementary Table 22. Association of neutrophil–lymphocyte ratio (NLR) with all-cause mortality, with and 
without adjustment for cell type proportion in Normative Aging Study. 
NLR association with mortality  
Without adjusting for cell proportions Adjusting for cell proportions 
HR (95% CI) p HR (95% CI) p 
without any CpG inclusion  1.08 (1.00 – 1.17) 0.04 1.06 (0.92 – 1.21) 0.43 
cg17086398 1.08 (1.00 – 1.17) 0.045 1.06 (0.93 – 1.21) 0.41 
cg14866069 1.13 (1.05 – 1.22) 0.002 1.03 (0.90 – 1.18) 0.68 
cg23666362 1.10 (1.02 – 1.19) 0.017 1.04 (0.90 – 1.20) 0.61 
cg12619262 1.08 (1.00 – 1.17) 0.042 1.05 (0.92 – 1.21) 0.45 
cg20045320 1.08 (1.00 – 1.17) 0.042 1.05 (0.92 – 1.20) 0.46 
cg07677157 1.09 (1.01 – 1.18) 0.034 1.06 (0.93 – 1.21) 0.39 
cg07839457 1.07 (0.99 – 1.15) 0.06 1.00 (0.88 – 1.15) 0.97 
cg18424841 1.10 (1.02 – 1.19) 0.02 1.06 (0.93 – 1.21) 0.38 
 
